ACE inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008

Journal of Managed Care Pharmacy

Volumn 16, Issue 9, 2010, Pages 671-679

  Bian, Boyang ^a   Kelton, Christina M L ^b   Guo, Jeff J ^c   Wigle, Patricia R ^d  

^a Pharmaceutical Sciences   (United States)

^b Economics and Adjunct Professor of Clinical Pharmacy   (United States)

^c Pharmacoeconomics and Pharmacoepidemiology   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS OLMESARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; CAPTOPRIL PLUS HYDROCHLOROTHIAZIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENALAPRIL MALEATE; ENALAPRIL MALEATE PLUS FELODIPINE; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; EPROSARTAN; FOSINOPRIL; GENERIC DRUG; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS MOEXIPRIL; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; LOSARTAN POTASSIUM; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; TRANDOLAPRIL PLUS VERAPAMIL; VALSARTAN;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COUGHING; DIABETES MELLITUS; DRUG COST; GOVERNMENT; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SERVICE; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; MARKET; MEDICAID; MICROANGIOPATHY; RETROSPECTIVE STUDY;

EID: 78649502688     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.9.671     Document Type: Article

References (35)

1. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206-52. Available at: http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf. Accessed September 3, 2010.
2. Writing group members, Lloyd-Jones D, Adams RJ, et al.; on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease & stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215. Epub 2009 Dec 17. Available at: http://circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.109.192667. Accessed September 3, 2010.
3. Dall TM, Zhang Y, Chen YJ, Quick WW, Yang WG, Fogli J. The economic burden of diabetes. Health Affairs. 2010;29(2):297-303.
4. Amann B, Tinzmann R, Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care. 2003;26(8):2421-25. Available at: http://care.diabetesjournals.org/content/26/8/2421.full.pdf+html. Accessed September 3, 2010.
5. Matchar DB, McCrory DC, Orlando LA, et al. Comparative effectiveness of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating essential hypertension. Agency for Healthcare Research and Quality. Comparative Effectiveness Review, no. 10. Publication no. 08-EHC003-EF. November 2007. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/12/45/ACEI_ARBFullReport.pdf. Accessed September 3, 2010.
6. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. FDA approved drug products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed September 3, 2010.
7. IMS Health. Top therapeutic classes by U.S. dispensed prescriptions. April 6, 2010. Available at: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Top%20Therapy%20Classes%20 by%20U.S.RXs.pdf. Accessed September 3, 2010.
8. Agency for Healthcare Research and Quality. ACEIs or ARBs for adults with hypertension: clinician's guide. October 2007. Available at: http://effectivehealthcare.ahrq.gov/ehc/products/12/32/ACEI-ARBClinician.pdf. Accessed September 3, 2010.
9. Waknine, Y. FDA approves first generic formulations of losartan for hypertension. Medscape Today. April 9, 2010. Available at: http://www.medscape.com/viewarticle/720003. Accessed September 3, 2010.
10. ONTARGET Investigators, Yusuf S, Teo KK, Pogue, Dyal L, et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547-59.
11. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases. October 2009. Available at: http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf. Accessed September 3, 2010.
12. Guo JJ, Jing Y, Nguyen K, Fan H, Li X, Kelton CM. Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in U.S. Medicaid programmes. J Med Econ. 2008;11(4):671-94.
13. Kaiser Commission on Medicaid and the Uninsured. State Medicaid outpatient prescription drug policies: findings from a national survey, 2005 update. October 8, 2005. Available at: http://www.kff.org/medicaid/7381.cfm. Accessed September 3, 2010.
14. Fischer MA, Avorn J. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans. Health Serv Res. 2003;38(4):1051-63.
15. BlueCross BlueShield of Texas. Step therapy guidelines for the City of Houston (COH) employees. March 2009. Available at: http://www.bcbstx.com/provider/pdf/step_therapy_guidelines.pdf. Accessed September 3, 2010.
16. Upper Peninsula Health Plan. Restricted drug classes list. Effective July 1, 2010. Available at: http://www.uphp.com/Pharmacy/RestDrugListJuly2010.pdf. Accessed September 3, 2010.
17. Centers for Medicare & Medicaid Services. State drug utilization data. Available at: http://www.cms.gov/MedicaidDrugRebateProgram/SDUD/list. asp. Accessed September 3, 2010.
18. Lewin Group. Medicaid managed-care cost savings-a synthesis of fourteen studies. Final report. Prepared for America's Health Insurance Plans. July 2004. Available at: http://www.ahipresearch.org/pdfs/MedicaidCostSavings.pdf. Accessed September 3, 2010.
19. Bureau of Labor Statistics. Consumer price index. Available at: http://www.bls.gov/cpi/. Accessed September 3, 2010.
20. Cox E, Behm A, Mager D. Express Scripts research study findings. 2005 generic drug usage report: executive summary. Available at: http://www.express-scripts.com/research/studies/pharmacybenefitresearch/benefitdesign/docs/genericDrugUsageReport2005.pdf. Accessed September 3, 2010.
21. Zuckerman S, Evans A, Holahan J. Questions for states as they turn to Medicaid managed care. The Urban Institute Series A, No. A-11. August 1997. Available at: http://www.urban.org/UploadedPDF/anf_a11.pdf. Accessed September 3, 2010.
22. Centers for Medicaid & Medicare Services. National summary of Medicaid managed care programs and enrollment as of June 30, 2008. Available at: http://www.cms.gov/MedicaidDataSourcesGenInfo/downloads/08Trends508.pdf. Accessed September 3, 2010.
23. The National Bureau of Economic Research. NBER Committee confers: no trough announced. April 12, 2010. Available at: http://www.nber.org/cycles/april2010.pdf. Accessed September 3, 2010.
24. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52(5):818-27. Available at: http://hyper.ahajournals.org/cgi/reprint/52/5/818. Accessed September 3. 2010.
25. Centers for Disease Control & Prevention. Crude and age-adjusted percentage of civilian, noninstitutionalized population with diagnosed diabetes, United States, 1980-2007. July 24, 2009. Available at: http://www.cdc.gov/diabetes/statistics/prev/national/figage.htm. Accessed September 3, 2010.
26. Baker WL, Coleman CI, Kluger J, Reinhart KM, Talati R, Quercia R, Phung OJ, White CM. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Ann Intern Med. 2009;151(12):861-71. Available at: http://www.annals.org/content/151/12/861.full.pdf+html. Accessed September 3, 2010.
27. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667-75.
28. McMurray JJ. ACE inhibitors in cardiovascular disease-unbeatable? N Engl J Med. 2008;358(15):1615-16. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMe0801925. Accessed September 3, 2010.
29. Yokoyama K, Yang W, Preblick R, Frech-Tamas F. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy. J Manag Care Pharm. 2007;13(3):235-44. Available at: http://www.amcp.org/data/jmcp/235-44. pdf.
30. Curtiss FR. Outcomes of sword swallowing and pharmaceutical steptherapy interventions. J Manag Care Pharm. 2007;13(3):284-86. Available at: http://www.amcp.org/data/jmcp/284-86.pdf.
31. Gleason PP. Assessing step-therapy outcomes: a step in the right direction. J Manag Care Pharm. 2007;13(3): 275-75. Available at: http://www.amcp.org/data/jmcp/273-75.pdf.
32. Fischer MA, Choudhry NK, Winkelmayer WC. Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? Health Aff. (Millwood). 2007;26(3):800-07.
33. Kaiser Commission on Medicaid and the Uninsured. Medicaid and managed care. December 2001. Available at: http://www.kff.org/Medicaid/upload/Medicaid-and-Managed-Care-Fact-Sheet.pdf. Accessed September 3, 2010.
34. Centers for Medicare & Medicaid Services. National summary of Medicaid managed care programs and enrollment as of June 30, 2008. Available at: http://www.cms.gov/MedicaidDataSourcesGenInfo/downloads/08Trends508.pdf. Accessed September 3, 2010.
35. Centers for Medicare & Medicaid Services. Medicaid drug rebate program: overview. April 20, 2010. Available at: http://www.cms.gov/MedicaidDrugRebateProgram. Accessed September 3, 2010.